
Van Heron Labs is a biotechnology company that leverages genetics, bioinformatics, and AI to optimize biological manufacturing and applications. Their proprietary platform analyzes cellular transcriptomes to identify optimal nutrient profiles for cell growth media, reducing guesswork and accelerating development cycles. The company aims to enhance the health of humans and the planet by enabling and improving bio-manufacturing. Their technologies are applicable across various industries including cellular agriculture, biologics, cell therapy, gene therapy, precision fermentation, and stem cell applications. They offer services like Ser-X for optimizing cultures and transitioning to chemically-defined media, with demonstrated improvements in cell density, protein output, and cost reduction.

Van Heron Labs is a biotechnology company that leverages genetics, bioinformatics, and AI to optimize biological manufacturing and applications. Their proprietary platform analyzes cellular transcriptomes to identify optimal nutrient profiles for cell growth media, reducing guesswork and accelerating development cycles. The company aims to enhance the health of humans and the planet by enabling and improving bio-manufacturing. Their technologies are applicable across various industries including cellular agriculture, biologics, cell therapy, gene therapy, precision fermentation, and stem cell applications. They offer services like Ser-X for optimizing cultures and transitioning to chemically-defined media, with demonstrated improvements in cell density, protein output, and cost reduction.
Founded: 2020
Headquarters: HudsonAlpha Institute for Biotechnology, Huntsville, Alabama
Core tech: Genetics, bioinformatics, AI-driven cellular analytics
Product / service: Media optimization (Ser-X) and biological digital-twin for cell performance
Recent funding signal: Seed round with FoodLabs; gbeta support
Media formulation and biomanufacturing optimization via cellular analytics
2020
Biotechnology
1100000
“FoodLabs lead investor; gbeta provided non-equity/accelerator support”